Team:Hong Kong HKUST/results

From 2013.igem.org

(Difference between revisions)

Latest revision as of 12:53, 28 October 2013

Result

Experiment 1: Glyoxylate Shunt

Introduce glyoxylate enzymes responsible for the shunt

Experiment 2: Protein Trafficking

Target ACE proteins into mitochondria

Experiment 3: Fatty Acid Sensing Mechanism

Introduce inducible system that allows tunable fatty acid uptake by sensing fatty acid concentration

Experiment 4: Cell Viability & Fatty Acid Quantification

Measuring cell viability at different fatty acid concentration & measure fatty acid uptake rate

Our project was first proposed in mid-March and after a series of improvement and elaboration, we started our wet lab work from mid-June to late-September. After 3 months of memorable diligent work, we are proud to claim that we have achieved the results below:

Successfully constructed two parts carrying mitochondrial leader sequence (MLS) compatible with RFC 10 and RFC 25 assembly standards respectively, (BBa_K1119000, BBa_K1119001).
Successfully constructed parts containing the aceA and aceB elements of the glyoxylate shunt (BBa_K1119002, BBa_K1119003).
Successfully constructed a part containing the constitutive CMV promoter (BBa_K1119006).
Successfully characterized the constitutive CMV promoter in HEK293FT cells (BBa_K1119008).
Successfully constructed a part containing the constitutive regulatory promoter of Human Elongation Factor 1-alpha (BBa_K1119010).
Successfully characterized the constitutive EF-1alpha promoter in HEK293FT cells (BBa_K1119011).
Successfully characterized the mitochondrial leader sequence (MLS) in HEK293FT cells (BBa_K1119009).
Successfully tested HepG2 cell viability in different sodium palmitate concentrations.

@@ Line 120: / Line 120: @@
 }
 #slide{width:96%;height:auto;background-color:#F4DFC0;margin-top:80px;border:2px solid;
-border-radius:15px;padding-right:10px;margin-left:15px;}
+border-radius:15px;padding-right:10px;margin-left:15px;font-family:"Trebuchet MS",Helvetica,sans-serif;float:left;}
+#slide1{width:96%;height:auto;background-color:#F4DFC0;margin-top:20px;border:2px solid;
+border-radius:15px;padding-right:10px;margin-left:15px;font-family:"Trebuchet MS",Helvetica,sans-serif;float:left;}
 .center
 {
@@ Line 128: / Line 130: @@
 }
 #interview,#presentation,#article, #interview1, #presentation1,#article1
-{margin-top:20px;width:30%;margin-right:20px;float:left;height:250px; border:2px solid;
+{margin-top:20px;width:23%;margin-right:10px;float:left;height:230px; border:2px solid;
 border-radius:15px;font-family:"Trebuchet MS", Helvetica, sans-serif;}
 #interview
-{margin-left:25px;background:#e32e51;}
+{margin-left:0px;background:#e32e51;}
 #interview1
-{margin-left:25px;background:#35bb91;}
+{margin-left:17px;background:#B0B0B0;}
-#presentation,#article1
+#presentation{background:#B0B0B0;}
+#article1
 {background:#35bb91;}
 #article,#presentation1
 {background:#e32e51;}
-#art-desc,#pre-desc,#int-desc{width:50%;float:right;margin-right:8px;}
+#art-desc,#pre-desc,#int-desc{width:50%;float:right;margin-right:7px;}
-#art-img,#pre-img,#int-img{width:45%;float:left;margin-left:5px;}
+#art-img,#pre-img,#int-img{width:45%;float:left;margin-left:4px;}
-#art-desc-text,#pre-desc-text,#int-desc-text{text-align:justify;float:right;}
+#art-desc-text,#pre-desc-text,#int-desc-text{float:right;}
 h3,h1,#yo{margin-left:10px;font-family:"Trebuchet MS", Helvetica, sans-serif;}
-h3.title{font-size:35px;}
+h3.title{font-size:38px;}
+#iGEM_Logo{
+width:100px;
+height:80px;
+position:absolute;
+right:10px;
+top:60px;
+z-index:+15;
+}
+#hkust_Logo{
+width:60px;
+height:80px;
+position:absolute;
+right:110px;
+top:60px;
+z-index:+15;
+}
 </style>
 </head>
 <body>
+           <a href="https://2013.igem.org/Main_Page"><img id="iGEM_Logo" src="https://static.igem.org/mediawiki/2013/4/46/Igem_qgem_logo.png"></a>
+<a href="http://www.ust.hk/eng/index.htm"><img id="hkust_Logo" src="https://static.igem.org/mediawiki/2013/5/55/Hkust_logo.gif"></a>
 <a href=https://2013.igem.org/Team:Hong_Kong_HKUST><center><div id="kepala"><img src="https://static.igem.org/mediawiki/igem.org/c/c7/BANNER1_%281%29.png" style="height:121px;width:100%;"></div></center></a>
@@ Line 168: / Line 194: @@
 <li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/abstract">Abstract</a></li>
 <li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/modules">Modules Description</a></li>
+<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/data">Data Page</a></li>
 <li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/Parts">Parts</a></li>
 <li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/characterization">Characterization</a></li>
-<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/modelling">Modeling</a></li>
 <li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/results">Result</a></li>
+<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/future">Future Work</a></li>
 </ul>
 </li>
@@ Line 180: / Line 207: @@
 <li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/protocols">Protocols</a></li>
 <li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/safety">Safety</a></li>
-<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/future">Future Work</a></li>
 </ul>
 </li>
@@ Line 193: / Line 220: @@
 <li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/hp">Human Practice</a>
 <ul>
-<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/hp/interview">Interviews</a></li>
 <li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/hp/cp">Country Profile</a></li>
 <li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/hp/blog">Blog</a></li>
-<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/hp/article">Article</a></li>
+<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/hp/interview">Interviews</a></li>
+<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/hp/article/genet">Article</a></li>
 <li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/hp/video">Videos</a></li>
 <li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/hp/presentation">Presentations</a></li>
@@ Line 206: / Line 233: @@
 </div>
 <br><br><br>
-<div id="slide"><center><h3 class="title">Result</h3></center>
+<div id="slide"><center><br><h3 class="title">Result</h3></center><br></div>
-<p id="yo">While low-fat diet and regular exercise are popular approaches to fight with obesity, one easy alternative is simply to increase energy metabolism. In a synthetic biology approach, we are working to create an artificial futile cycle in mammalian cell by introducing glyoxylate enzymes native to bacteria. Past research has shown that mice expressing enzymes constituting an active glyoxylate shunt are shown to be resistant to diet-induced obesity. Our team plans to introduce an inducible system that allows us to couple the sensing of circulating fatty acid concentrations with an inducible circuit of glyoxylate shunt. Our inducible system is intended to prevent the risk of fatty acid deficiency, while facilitating greater fatty acid uptake at higher fatty acid circulating concentrations. Such a system should increase the feasibility of a glyoxylate cycle engineered to function in vivo. </p>
+<div id="interview1"><h3>Experiment 1: Glyoxylate Shunt</h3><div id="art-img"><br><img src="https://static.igem.org/mediawiki/2013/c/c0/Expt3.png" style="padding-left:5px;width:90%;padding-top:5px;"><center><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/experiment/exp4"><img src="http://w1ggroup.com/devere/img/more_off.png" style="width:80%;height:40px;padding-top:10px;"></a></center></div><div id="art-desc"><p id="art-desc-text"><br>Introduce glyoxylate enzymes responsible for the shunt</p></div></div>
-<br><br>
-</div>
+<div id="interview"><h3>Experiment 2: Protein Trafficking</h3><div id="pre-img"><br><img src="https://static.igem.org/mediawiki/2013/4/45/Expt2.png" style="padding-left:5px;width:105%;padding-top:8px;"><center><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/experiment/exp3"><br><img src="http://w1ggroup.com/devere/img/more_off.png" style="width:75%;height:40px;padding-top:2px;"></a></center></div><div id="pre-desc"><p id="pre-desc-text"><br>Target ACE proteins into mitochondria</p></div></div>
+<div id="presentation"><h3>Experiment 3: Fatty Acid Sensing Mechanism</h3><div id="pre-img"><br><img src="https://static.igem.org/mediawiki/2013/4/4f/Expt1.png" style="padding-left:5px;padding-top:5px;width:90%;"><center><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/experiment/exp2"><img src="http://w1ggroup.com/devere/img/more_off.png" style="width:80%;height:40px;padding-top:10px;"></a></center></div><div id="pre-desc"><p id="pre-desc-text"><br>Introduce inducible system that allows tunable fatty acid uptake by sensing fatty acid concentration</p></div></div>
+<div id="article"><h3>Experiment 4: Cell Viability & Fatty Acid Quantification</h3><div id="pre-img"><br><img src="https://static.igem.org/mediawiki/2013/f/fa/Expt0.png" style="padding-left:2px;padding-top:5px;width:90%;"><center><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/experiment/exp1"><img src="http://w1ggroup.com/devere/img/more_off.png" style="width:80%;height:40px;padding-top:10px;"></a></center></div><div id="pre-desc"><br><p id="pre-desc-text">Measuring cell viability at different fatty acid concentration & measure fatty acid uptake rate</p></div></div>
+<div id="slide1">
+<p id="yo">Our project was first proposed in mid-March and after a series of improvement and elaboration, we started our wet lab work from mid-June to late-September. After 3 months of memorable diligent work, we are proud to claim that we have achieved the results below:
+<ul>
+  <li>Successfully constructed two parts</a> carrying mitochondrial leader sequence (MLS) compatible with RFC 10 and RFC 25 assembly standards respectively, (<a href="http://parts.igem.org/Part:BBa_K1119000">BBa_K1119000</a>, <a href="http://parts.igem.org/Part:BBa_K1119001">BBa_K1119001</a>).</li>
+  <li>Successfully constructed </a>parts containing the <i>aceA</i> and <i>aceB</i> elements of the glyoxylate shunt (<a href="http://parts.igem.org/Part:BBa_K1119002">BBa_K1119002</a>, <a href="http://parts.igem.org/Part:BBa_K1119003">BBa_K1119003</a>). </li>
+  <li>Successfully constructed a part containing the constitutive CMV promoter (<a href="http://parts.igem.org/Part:BBa_K1119006">BBa_K1119006</a>).</li>
+  <li>Successfully characterized the constitutive CMV promoter in HEK293FT cells (<a href="http://parts.igem.org/Part:BBa_K1119008">BBa_K1119008</a>).</li>
+ <li>Successfully constructed a part containing the constitutive regulatory promoter of Human Elongation Factor 1-alpha (<a href="http://parts.igem.org/Part:BBa_K1119010">BBa_K1119010</a>).</li>
+<li>Successfully characterized the constitutive EF-1alpha promoter in HEK293FT cells (<a href="http://parts.igem.org/Part:BBa_K1119011">BBa_K1119011</a>).</li>
+  <li>Successfully characterized the mitochondrial leader sequence (MLS) in HEK293FT cells (<a href="http://parts.igem.org/Part:BBa_K1119009">BBa_K1119009</a>).</li>
+  <li>Successfully tested HepG2 cell viability in different sodium palmitate concentrations. </li>
+</ul></p>
+<br>
+</div>
+</body>
 </html>